(Q41106514)

26 September 2017

1 reference

title

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure (English)

1 reference

26 September 2017

0 references

chronic heart failure

1 reference

Struthers AD

1

1 reference

26 September 2017

1 March 1996

1 reference

Journal of Cardiac Failure

26 September 2017

1 reference

26 September 2017

2

1 reference

26 September 2017

1

1 reference

26 September 2017

47-54

1 reference

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Captopril in heart failure. A double blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium Retention

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Changes of fractional renal clearance of magnesium after spironolactone administration in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effect of magnesium on anginal attack induced by hyperventilation in patients with variant angina.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Prognostic importance of the serum magnesium concentration in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Depressant effect of magnesium on early afterdepolarizations and triggered activity induced by cesium, quinidine, and 4-aminopyridine in canine cardiac Purkinje fibers

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Role of dietary magnesium deficiency in the pressor and arrhythmogenic response to epinephrine in the intact dog.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Short- and long-term mechanisms of sudden cardiac death in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

A kinetic analysis of the extraneuronal uptake and metabolism of catecholamines

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Aldosterone reduces baroreceptor discharge in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Chronic administration of aldosterone depresses baroreceptor reflex function in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Decreased heart rate variability and its association with increased mortality after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Protective effect of vagal stimulation on reperfusion arrhythmias in cats

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Cardiac vagal activity: a target for intervention in heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Coronary reserve is depressed in postmyocardial infarction reactive cardiac hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Vasodilation to acetylcholine in primary and secondary forms of human hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Reactive and reparative myocardial fibrosis in arterial hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

QT dispersion and sudden unexpected death in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Ectopic arrhythmia provoking action of aldosterone

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Diurnal variations of plasma aldosterone in supine man: relationship to plasma renin activity and plasma cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Circadian variation in the frequency of sudden cardiac death

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

Current and ongoing randomized trials in heart failure and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980009-1

7 January 2021

10.1016/S1071-9164(96)80009-1

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8798105